#254 Mark Pimentel, is Professor of Medicine at Geffen School of Medicine and Cedars-Sinai Medical Center in Los Angeles. He is also the Executive Director of the Medically Associated Science and Technology (MAST) Program at Cedars-Sinai Medical Center. Dr. Pimentel completed 3 years of an undergraduate degree in honors microbiology and biochemistry. This was followed by his medical degree, and his BSc (Med) from the University of Manitoba Health Sciences Center, where he also completed a residency in internal medicine. His medical training includes a fellowship in gastroenterology at the UCLA Affiliated Training Program. Active in research, Dr. Pimentel has served as a principal investigator or co-investigator for numerous basic science, translational and clinical studies in such areas as IBS, and the relationship between gut flora composition and human disease. His work has been published in the New England Journal of Medicine, Annals of Internal Medicine, American Journal of Physiology, American Journal of Medicine, American Journal of Gastroenterology and Digestive Diseases and Sciences, among others. Dr. Pimentel is a diplomate of the American Board of Internal Medicine (Gastroenterology) and a fellow of the Royal College of Physicians and Surgeons of Canada.

  In this episode we cover

• Exciting new developments with SIBO research
• What the research says on PPI’s increasing the risk of SIBO
• Current treatment for hydrogen sulphide treatment
• Why methane overgrowth (IMO) is so stubborn to treat
• Sibo diet post active treatment - how long to keep people on it
• The impact of ageing on the small intestine and the link between Scleroderma and antivinculin antibodies
• The preferred substrate for SIBO breath testing
• The Microbiome Connection book
• And so much more